About Katie Reiley

This author has not yet filled in any details.
So far Katie Reiley has created 94 blog entries.

From Hot Mess to High-Performing: Building a Scalable Third-Party Due Diligence Program

Does your third-party due diligence process feel more like controlled chaos than a streamlined strategy? In today’s rapidly evolving regulatory landscape, life sciences organizations are struggling to balance comprehensive risk assessments with the need for speed, scale and cross-functional collaboration.

In this insightful webinar we’ll guide you through transforming a fragmented third-party risk program into a […]

From Hot Mess to High-Performing: Building a Scalable Third-Party Due Diligence Program2025-08-06T16:57:54+00:00

MediSpend Acquires Alucio to Expand AI-Enabled Stakeholder Engagement Capabilities

Portsmouth, NH – August 4, 2025 — MediSpend, a global leading provider of compliance and stakeholder engagement solutions for the life sciences industry, announces its acquisition of Alucio, an innovative technology company known for its AI-enabled content management and HCP engagement platform, BEACON. The acquisition enhances MediSpend’s offerings to support more effective scientific exchanges between life […]

MediSpend Acquires Alucio to Expand AI-Enabled Stakeholder Engagement Capabilities2025-08-04T12:40:10+00:00

What Life Sciences Companies Need in a Third-Party Due Diligence Platform

In today’s highly regulated global environment, pharmaceutical, biotech and medical device companies are under increasing pressure to demonstrate compliance across their extended third-party networks. From anti-bribery enforcement to FDA debarment risk to global supply chain integrity, life sciences organizations need more than just spreadsheets and checklists to manage their third-party risk. 

A modern […]

What Life Sciences Companies Need in a Third-Party Due Diligence Platform2025-07-08T21:43:11+00:00

Italy’s Sunshine Act: Implementation Advances After Three-Year Wait

After its passage in June 2022, Italy’s Sunshine Act (Law 62/2022) is finally moving toward implementation—marking a significant development in life sciences transparency. The law introduces mandatory reporting obligations for financial relationships between life sciences companies and healthcare professionals (HCPs) or healthcare organizations (HCOs), including transfers of value (ToVs), financial interests, and service agreements.

Key Milestones […]

Italy’s Sunshine Act: Implementation Advances After Three-Year Wait2025-05-29T13:37:13+00:00

Strengthening Compliance in Transparency Programs: Key Lessons from Recent DOJ Settlement (Pt. 2)

This is Part 2 in our blog series exploring a recent government enforcement action. Haven’t read Part 1 which covers speaker program compliance risks? Be sure to check it out here.

Recently, the Department of Justice (DOJ) reached a settlement with a global pharmaceutical company, resolving allegations that one of its subsidiaries paid kickbacks to […]

Strengthening Compliance in Transparency Programs: Key Lessons from Recent DOJ Settlement (Pt. 2)2025-04-23T16:45:16+00:00

Strengthening Compliance in Speaker Programs: Key Lessons from Recent DOJ Settlement (Pt. 1)

Since the Office of the Inspector General (OIG) issued its Special Fraud Alert in November 2020, speaker programs have remained under intense regulatory scrutiny. Recently, the Department of Justice (DOJ) reached a settlement with a global pharmaceutical company, resolving allegations that one of its subsidiaries paid kickbacks to healthcare providers (HCPs) to drive prescriptions of […]

Strengthening Compliance in Speaker Programs: Key Lessons from Recent DOJ Settlement (Pt. 1)2025-04-23T15:16:40+00:00

Real Life Sciences: Advanced Anonymization For Clinical Trial Disclosure

MediSpend recently acquired Real Life Sciences (RLS), the leading provider of clinical data and documents anonymization and redaction for the life sciences industry. Their platform, RLS Protect, is the industry leading solution which helps trial sponsors prepare required regulatory disclosure submissions and clinical data for sharing purposes.

Listen as Elliot Zimmerman, CEO of RLS, shares […]

Real Life Sciences: Advanced Anonymization For Clinical Trial Disclosure2025-02-26T17:55:49+00:00

DOJ’s ECCP Updates: Navigating Whistleblower Programs and Emerging Risks

In September 2024, the Department of Justice (DOJ) released an updated version of its Evaluation of Corporate Compliance Programs (ECCP) Guidance. The ECCP serves as a framework for DOJ prosecutors to evaluate a company’s compliance program when considering the appropriate enforcement actions. While updates were made across multiple topics, the most notable changes focus on […]

DOJ’s ECCP Updates: Navigating Whistleblower Programs and Emerging Risks2025-02-20T15:12:05+00:00

Unlocking the Value of Event Management Systems in the Life Science Industry

Pharmaceutical and medical device companies operate in a highly regulated and competitive landscape where efficient, compliant event management is essential. From medical congresses and training workshops to key opinion leader (KOL) meetings, these events shape industry relationships and drive innovation. As companies evaluate event management systems, they look for solutions that streamline processes, deliver educational […]

Unlocking the Value of Event Management Systems in the Life Science Industry2025-02-13T15:48:26+00:00

DOJ’s ECCP Updates: Managing AI and Emerging Tech Risks in Compliance

In September 2024, the Department of Justice (DOJ) released an updated version of its Evaluation of Corporate Compliance Programs (ECCP) Guidance. The ECCP serves as a framework for DOJ prosecutors to evaluate a company’s compliance program when considering the appropriate enforcement actions. While updates were made across multiple topics, the most notable changes focus on […]

DOJ’s ECCP Updates: Managing AI and Emerging Tech Risks in Compliance2025-02-05T18:40:10+00:00
Go to Top